Context Therapeutics Inc.

Context Therapeutics Inc. announced its inclusion in the small-cap Russell 2000® Index and the broad-market Russell 3000® Index. This inclusion became effective at the close of U.S. equity markets on June 26, 2026. The Russell Indexes are widely used by investment managers for index funds and as benchmarks for active investment strategies, providing increased visibility for the company.

Context Therapeutics Inc. held its Annual Meeting of Stockholders where shareholders approved an amendment to the company's Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000. Additionally, seven director nominees were elected to the Board, and CohnReznick LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Context Therapeutics Inc. announced positive interim efficacy and safety results from its ongoing Phase 1 clinical trial for CTIM-76, an investigational Claudin 6 x CD3 T cell engaging bispecific antibody. The data, from advanced, late-line platinum-resistant ovarian cancer (PROC) patients, showed a 29% confirmed overall response rate and a 57% disease control rate. The drug demonstrated a favorable safety profile with limited Grade 1 Cytokine Release Syndrome (CRS). CTIM-76 has received FDA Fast Track Designation, and the company plans to explore a Q3W dosing schedule.

Context Therapeutics announced positive interim Phase 1 clinical data for its CLDN6 x CD3 T cell engaging bispecific antibody, CTIM-76, in advanced, late-line platinum-resistant ovarian cancer (PROC). The study demonstrated a 29% overall response rate (ORR) and a 57% disease control rate (DCR) in efficacy-evaluable PROC patients at active doses, with a favorable safety profile showing Grade 1 cytokine release syndrome (CRS) in only 11% of patients. The pharmacokinetic profile supports exploring a Q3W dosing schedule in the second half of 2026, with Phase 1b dose expansion anticipated in 2027. CTIM-76 has also received FDA Fast Track Designation for PROC.

Context Therapeutics Inc. announced it granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement for accepting employment. The options were granted on May 26, 2026, with an exercise price of $2.63 per share, and vest over four years. Additionally, the company will present at the Jefferies Global Healthcare Conference on June 3, 2026.

Context Therapeutics announced an amendment to its exclusive license agreement with BioAtla, Inc. for CT-202, its Nectin-4 x CD3 T cell engager. The amendment eliminates all future milestone and royalty obligations for CT-202 in exchange for a $4.5 million upfront payment and a final $2.0 million payment due by August 1, 2026. This transaction provides Context with full economic rights to CT-202, a key program in its pipeline, with the Phase 1 trial expected to begin in the third quarter of 2026.

Context Therapeutics reported a net loss of $8.7 million for the first quarter of 2026, an increase from $4.6 million in Q1 2025. The company announced significant pipeline progress, including FDA Fast Track Designation for CTIM-76 for platinum-resistant ovarian cancer. Interim Phase 1a data for CTIM-76 is expected in June 2026, and for CT-95 in September 2026. Cash and cash equivalents of $54.5 million as of March 31, 2026, are expected to fund operations into mid-2027.

Context Therapeutics Inc. reported a net loss of $(8.68) million for the first quarter of 2026, a significant increase from $(4.58) million in the same period last year. The company's cash and cash equivalents decreased to $54.5 million as of March 31, 2026, with cash used in operating activities totaling $(11.43) million for the quarter. Research and development expenses more than doubled to $7.02 million as the company advances its clinical-stage product candidates, contributing to an accumulated deficit of $139.6 million.

Context Therapeutics Inc. announced the resolution of a stockholder class action lawsuit. The Delaware Court approved a stipulation deeming certain charter provisions, including 3-year director terms and removal only for cause, invalid and unenforceable. The Company filed a Certificate of Correction to reflect these changes. A third-party service provider agreed to pay the $850,000 mootness fee to plaintiff's counsel, which was paid on May 1, 2026, leading to the dismissal of the action. The case will officially close after the 2026 annual meeting quorum is confirmed.

Context Therapeutics Inc. will hold its 2026 Annual Meeting of Stockholders virtually on Wednesday, June 24, 2026. Stockholders will vote on the election of seven director nominees, the ratification of CohnReznick LLP as the independent registered public accounting firm for fiscal year 2026, and a proposal to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000. An additional proposal for adjournment is included if necessary to solicit further proxies for the share increase.